An observational study in Cerebral AV Malformation, sponsored by Microvention-Terumo, Inc.. Terminated at 16 sites in 5 countries. Open to participants aged 28 Days and older. Per ClinicalTrials.gov, last updated 2021-07-29.
Sponsored by Microvention-Terumo, Inc. (part of Terumo Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Intracranial Arteriovenous Malformations with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Intracranial Arteriovenous Malformations · France.
Among the 12 studies in Intracranial Arteriovenous Malformations with a site in France, this one is the only one that started in 2017, is one of 6 observational ones, and was the 3rd registered.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
Browse Intracranial Arteriovenous Malformations studies →6 of the 12 studies in Intracranial Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Balt Extrusion · Sites in France, Germany, Spain
Ages 2+
Hospices Civils de Lyon · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 0+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 11 Intracranial Arteriovenous Malformations studies recruiting now, 8 (73%) set no upper age limit and 2 (18%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 28 Days and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.
Median enrollment 66 across the 6 interventional studies, 126 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Microvention-Terumo, Inc., one of the names counted as Terumo Corporation. Under that name alone:
Microvention-Terumo, Inc. is the lead sponsor of 32 studies on the registry; 7 are open to participants now.
Terumo Corporation has 1 study filed under Intracranial Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Intracranial Arteriovenous Malformations with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy and safety of PHIL® liquid embolic agent in endovascular embolization of cerebral arteriovenous malformations.
This is an European multi-center observational study. Treatments and follow-up visits will be done as per standard of care.
The objective of this study is to evaluate the efficacy and safety of the PHIL® device in the treatment of intracranial cerebral arteriovenous malformation. The PHIL® device, a non-adhesive liquid embolic agent, has been CE marked since July 2014. It is intended for use in the embolization of lesions in the peripheral and neurovasculature, including arteriovenous malformations and hypervascular tumors.
All patients with a cAVM, ruptured or unruptured, eligible for endovascular treatment with a liquid embolic agent, PHIL®, based on multidisciplinary consensus are eligible for this study. A maximum of 108 patients will be enrolled in 18 European Institutions.
The expected approximate study duration is 39 months.
All patients with a cAVM, ruptured or unruptured, eligible for endovascular treatment with a liquid embolic agent, PHIL®, based on multidisciplinary consensus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall cure rate
Time frame: immediately after final embolization
Cure rate with regard to the aim of the endovascular treatment
Time frame: immediately after final embolization
Overall cure rate
Time frame: 3-6 months
Cure rate with regard to the aim of the endovascular treatment
Time frame: 3-6 months
Clinical outcome compared to baseline
Assessment by mRS
Time frame: up to 3 days
Clinical outcome compared to baseline
Assessment by mRS
Time frame: 1 month after each embolization
Clinical outcome compared to baseline
Assessment by mRS
Time frame: 3-6 months after the final embolization
Adverse Events
AE related to the PHIL procedure and/or to the techniques used during each embolization
Time frame: 1 months after last embolization
Total volume of injected PHIL
Time frame: during each embolization
Volume/superselective injection
Time frame: during each embolization
Length of reflux of PHIL
Time frame: during each embolization
Amount of pedicles catheterized
Time frame: during each embolization
Overall injection time
Time frame: during each embolization
Overall radiation dose given to the patient during EVT
Time frame: during each embolization
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2017 to primary completion in Oct 2020, 35 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriovenous Malformations →